Physician profile
Taraneh Tehrani
NPI 1689731648
$977.80
in general payments reported to CMS, 2019-2025
12 companies · $175 in 2025
The $175 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $120 · 2022: $115 · 2023: $121 · 2024: $447 · 2025: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $742.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $266.11 | 2021-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $122.28 | 2024 | |
| Abiomed | $120.59 | 2024-2025 | Impella |
| Pfizer INC. | $88.45 | 2021 | |
| Merck Sharp & Dohme LLC | $75.36 | 2024 | Dificid |
| Shionogi INC | $74.75 | 2023-2024 | Fetroja |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.88 | 2022-2024 | Jardiance |
| Verona Pharma, INC. | $48.46 | 2025 | Ohtuvayre |
| E.R. Squibb & Sons, L.L.C. | $46.19 | 2022-2023 | Eliquis |
| Gilead Sciences, INC. | $28.47 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $24.00 | 2025 | Lifevest |
| Cytovale, INC. | $21.26 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taraneh Tehrani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.